News | May 13, 2026
Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
The partnership covers the entire product lifecycle from early-stage development through commercialization
The partnership covers the entire product lifecycle from early-stage development through commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The private funding rose 38% amid growing international collaborations and CDMO demand
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Subscribe To Our Newsletter & Stay Updated
